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Abstract
Background: As the most incident tumor among women worldwide, breast cancer 
is a heterogeneous disease. Tremendous efforts have been made to understand 
how tumor characteristics as histological type, molecular subtype, and tumor 
microenvironment collectively influence disease diagnosis to treatment, which impact 
outcomes. Differences between populations and environmental and cultural factors 
have impacts on the origin and evolution of the disease, as well as the therapeutic 
challenges that arise due to these factors. We, then, compared copy number variations 
(CNVs) in mucinous and nonmucinous luminal breast tumors from a Brazilian cohort 
to investigate major CNV imbalances in mucinous tumors versus non‐mucinous 
luminal tumors, taking into account their clinical and pathological features.
Methods: 48 breast tumor samples and 48 matched control blood samples from 
Brazilian women were assessed for CNVs by chromosome microarray. Logistic 
regression and random forest models were used in order to assess CNVs in 
chromosomal regions from tumors.
Results: CNVs that were identified in chromosomes 1, 5, 8, 17, 19, and 21 classify 
tumors according to their histological type, ethnicity, disease stage, and familial 
history.
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1 |  INTRODUCTION
As the most incident tumor among women worldwide, breast 
cancer also causes the highest number of deaths in the female 
population, especially in developing countries where the diag-
nosis of late‐stage disease is made in most cases (World Health 
Organization, 2018). Breast cancer is also a heterogeneous dis-
ease, where the individual's genetics in combination with the 
influence of tumor histological type, molecular subtype, and 
tumor microenvironment contribute to disease progression. A 
better understanding of these factors in relation to early diagno-
sis and disease treatment impacting overall survival is critical 
(Cecilio et al., 2015). In addition, differences between popula-
tions and also environmental and cultural factors significantly 
affect the origin and evolution of the disease, and therefore 
bring additional therapeutic challenges (IARC, 2014).
Ductal carcinomas account for more than 70% of breast 
tumors and include all histological types that cannot be clas-
sified into defined types. Their prognosis depends mainly on 
the molecular subtype and other features such as stage that 
includes tumor size, affected lymph nodes, and the presence 
of metastasis (IARC, 2014). Among the histological types 
of breast tumors, mucinous carcinomas of the breast are rare 
and comprise 1%–6% of all breast tumor cases, especially in 
women over 75 years of age (Ha, Deleon, & Deleon, 2013). 
Genomic studies involving this type of tumor are understud-
ied, in part because of its low incidence. A portion of the 
cases that did not respond well to standard‐of‐care treatments 
were characterized as presenting positivity for ERBB2 and 
P53, with a higher probability of metastasis. Cases that pres-
ent the mucinous histological type in less than 90% of the 
tumor or, in association with invasive ductal tumors, also 
tend to be more aggressive (Lacroix‐Triki et al., 2010). In 
addition, chromosome analysis in pure mucinous tumors in 
conjunction with other histological types showed gains in 
1q and 16p arms and losses in the 16q and 22q arms, de-
spite lower genetic instability compared to invasive ductal 
tumors. Studies have shown that a number of genes such as 
ERBB2, FGFR1, CCND1, FGF3, FGF4, FGF19, PIK3CA, 
BRCA1, TSC2, STK11, AKT3, and ESR1, among others, pres-
ent changes in tumors of this type (Lei, Yu, Chen, Chen, & 
Wang, 2016; Ross et al., 2016). Hence, a better understanding 
is needed of altered genomic landscape in aggressive, treat-
ment‐refractory mucinous breast tumors.
Majority of defined breast cancer molecular subtypes 
were derived from ductal invasive breast tumors, and largely 
lacked profiling from other histological types of breast tu-
mors (Dieci, Orvieto, Dominici, Conte, & Guarneri, 2014; 
Perou et al., 2000; The Cancer Genome Atlas [TCGA], 2012). 
Few studies have described how molecular features from dif-
ferent histological types may influence treatment response 
(Caldarella et al., 2013; Weigelt et al., 2008). Mucinous tu-
mors are often described as Luminal A, and recent studies 
have shown that this subtype tended to have worse responses 
to cytotoxic agents and develop resistance to chemotherapy 
compared earlier to other histological subtypes (Araki & 
Miyoshi, 2018; Martelotto, Ng, Piscuoglio, Weigelt, & Reis‐
Filho, 2014).
Although breast cancer comes in many histological forms, 
the mucinous histological type remains understudied, in part 
due to its low incidence. In addition, the Brazilian popula-
tion of breast cancer patients is understudied regardless of 
the tumor phenotype. Current demographic data shows that 
the Brazilian population is composed of mixed ethnicities 
(Instituto Brasileiro de Geografia e Estatística [IBGE], 2018). 
Since Brazil is a genetically underrepresented population, 
studies that include Brazilian cohorts may uncover previously 
unknown genetic drivers of therapeutic resistance and lead to 
the discovery of new biomarkers. The genetic composition 
of tumors in the Brazilian population is also dissimilar from 
that of populations living in other regions of the globe, even 
in neighboring Latin America countries, since the patterns of 
colonization and intrinsic miscegenation between colonizers 
and the native populations vary markedly across these coun-
tries (Giolo et al., 2012; Popejoy & Fullerton, 2016).
In this study, we compare the genomic features in terms of 
copy number variations (CNVs) in mucinous and nonmucinous 
luminal breast tumors of a Brazilian cohort. With this method-
ological approach, we were able to describe major CNV imbal-
ances in mucinous tumors versus ordinary luminal A/B tumors 
in association with clinical and pathological features.
2 |  SUBJECTS AND METHODS
The procedures for obtaining the samples used in this study, 
as well as the informed consent form signed by all the women 
participating in this study, followed the recommendations 
Conclusion: Copy number alterations described in this study provide a better 
understanding of the landscape of genomic aberrations in mucinous breast cancers 
that are associated with clinical features.
K E Y W O R D S
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of the Declaration of Helsinki and were approved by the 
Research Committee of CAISM—Women's Hospital/
UNICAMP (approved project n.° 082/2013) on 12/12/2013 
and by the Research Ethics Committee of UNICAMP and 
CONEP—National Research Committee (approved project 
n.° 1.166.843) on 7/30/2015. Tumor and blood samples 
of women who agreed to participate in the study and 
signed the consent form for this purpose were collected 
by the Division of Gynecological Oncology and Breast 
Pathology of CAISM—Women's Hospital/UNICAMP. 
Medical records were reviewed to obtain women clinical 
and epidemiological data. For this study, only ductal and 
mucinous tumors with or without other minor components 
were selected after the histopathological characterization of 
the biopsy. A skilled pathologist selected tumor and normal 
areas for microdissection. Tumor areas were used to obtain 
10μm fragments from which DNA extraction using phenol/
chloroform protocol was performed. A similar protocol was 
used for DNA retrieval from blood samples.
DNA was verified in agarose gel and considered ad-
equate only when hosting >80% of integrity. DNA was 
then diluted at concentrations between 40 and 60  ng/
μl, which were verified by the Epoch spectrophotometer 
(Biotek®, Winooski, VT). These concentrations are suit-
able for use with Affymetrix® Cytoscan™ HD Array assay 
kits (Thermo Fisher Scientific Inc., Santa Clara, CA). The 
protocol was performed as per manufacturer recommenda-
tions, comprising the steps of preparing the genomic DNA, 
digestion, ligation, PCR, purification, quantification, 
fragmentation, labeling, hybridization, washing, staining, 
and chip scanning. After scanning, data was processed by 
Affymetrix Molecular Diagnostic Software (AMDS) and 
quality control was generated by ChAS analysis software 
(Chromosome Analysis Suite, Affymetrix®). About 48 
chips were hybridized for the tumor samples and 48 chips 
for the blood samples of the same woman, the latter being 
used as control of constitutive CNVs.
For CNV analysis, data were normalized via the ASCRMA 
and raw copy algorithms. Then, the normalized data was seg-
mented using the Parent‐specific circular binding segmen-
tation (Olshen et al., 2011), copynumber, GADA, and CBS 
protocols. Only alterations contemplating at least 25 microar-
ray probes for deletions or 50 probes for amplifications were 
considered, along with fragments of 100kb with low‐rank 
representation (LRR) ≤ −0.3 for deletions and LRR ≥0.3 for 
amplifications. The data were also evaluated by the intersec-
tion of methods performed and described above: only sam-
ples with CNVs present in three or more of the methods were 
considered as altered for the variation of interest. Afterward, 
two statistical tests were applied to rank the most relevant 
CNVs by comparing between ductal and mucinous samples 
and also to evaluate the most relevant CNVs in relation to the 
clinical and pathological characteristics. Functional pathways 
associated with these CNVs were searched using DAVID 6.8 
(The Database for Annotation, Visualization and Integrated 
Discovery, p‐value ≤0.05) (Huang, Sherman, & Lempicki, 
2009) and UCSC Table Browser was used to retrieve infor-
mation on variants already described that are in association 
with the verified CNVs.
3 |  RESULTS
Table 1 shows the clinical and epidemiological features of 
the women included in the study, per tumor histological type. 
The majority of the women were above 45 years of age and 
were postmenopausal. Disease stage was predominantly I 
or II. About 81% of the women were Caucasian versus 19% 
Afro‐descendants. Fourteen women reported one or more 
cases of breast cancer in their families. Majority of the cases 
(n = 35) were classified as Luminal A, 11 Luminal B and 2 
Luminal B/HER2 enriched.
The frequencies of CNVs, by chromosome, in relation to 
clinical/pathological data are shown in Table 2. Interestingly, 
the altered chromosomes that relate both to later disease stage 
as to the presence of family history were found to be associ-
ated with CNVs on the same chromosomes (chr 5, 19 and 21), 
T A B L E  1  Description of the clinical and epidemiological 




n % n %
Age at diagnosis
35–45 0 0 3 6
>45 10 21 35 73
Ethnicity
Caucasian 9 19 30 62
Afro‐descendant 1 2 8 17
Menopausal status
Post 9 19 28 58
Pre 1 2 10 21
Disease stage
I/II 9 19 27 57
III 1 2 11 22
Familial history—breast 
cancer
Yes 1 2 13 27
No 9 19 25 52
Molecular subtype
Luminal A 7 15 28 58
Luminal B 1 2 10 21
Luminal B/HER2 2 4 0 0
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although higher levels of CNVs in chromosome 19 (46%) were 
associated with late stage and chromosome 21 (49%) for fam-
ily history presence. For histological type, comparing ductal to 
mucinous breast carcinomas, CNVs in chromosomes 8 and 1 
account for almost 49% of all alterations found in the mucinous 
tumors analyzed. Similarly, CNVs in chromosome 19 sum to 
46.27% of alterations related to later disease stage, alterations in 
chromosome 21 sum to 49.42% for familial history presence and 
chromosomes 1 and 17 sum to 31.08% for ethnicity (Caucasian).
Table 3 describes the genes related to CNVs in each 
chromosome, according to the features they were most as-
sociated with. Logistic Regressions and Random Forests 
models were used to assess these regions, comparing the 
genomic profiles of the samples, in which a power of dis-
crimination (AUC) of 73% was obtained. The CNVs rank-
ing data distinguishing between histological types and 
other clinical/pathological tumors’ characteristics were as-
sessed to evaluate how these alterations contributed to the 
separation between considered groups.
Table 4 summarizes the annotation findings in terms of func-
tional pathways closely associated to the CNV‐related genes found 
in the most altered chromosomes, depending on the analyzed trait. 
Pathways involved with alternative splicing and polymorphisms 
were mainly associated with most of the altered regions.
Supplementary Table S1 shows the variants already de-
scribed associated with the CNVs found in this study. The 
information of cancer‐related phenotypes, genes, and clinical 
status was assessed in order to better describe variants and 
their clinical interpretation. It is worth noting that all vari-
ants have been previously linked to breast or other forms of 
human neoplasms and roughly 60% of the CNVs found are of 
uncertain significance or have conflict of interpretation. Our 
observations add up to this data to be part of a more accurate 
interpretation in the future.
4 |  DISCUSSION
The results shown describe altered chromosome regions that 
better classify tumors according to their histological type, 
Chromosome Percentage
Disease stage chr19 46.27
chr21 35.07
chr5 18.66
Familial history chr21 49.42
chr19 28.79
chr5 21.79
T A B L E  2  (Continued)T A B L E  2  Percentage of CNVs found, by chromosome, including 
association with clinical and pathological features
Chromosome Percentage
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ethnicity, disease stage, and familial history. For this set of 
tumors, almost half of the alterations were found in chromo-
somes 8 and 1 when considering mucinous tumors compared 
to ductal breast carcinomas, in chromosome 19 when con-
sidering the later disease stage when comparing to earlier 
stages, in chromosome 21 when comparing presence of fam-
ily history to its absence and virtually 1/3 of the changes were 
found on chromosomes 1 and 17 when ethnicity (Caucasian 
X Afro‐descendants) was considered. Also, genes found 
in CNVs regions described in this study were significantly 
enriched in gene sets related to alternative splicing, poly-
morphisms, DNA‐binding, transcriptional regulation, phos-
phoproteins, and mutagenic sites, among others.
Polymorphisms of single nucleotides or of larger DNA 
fragments and all the other abovementioned pathways are 
widely associated with the development of cancer in gen-
eral. Aberrant activation of these pathways in breast cancer 
is part of the oncogenic mechanisms contributing to disease 
progression and is the focus of many current studies, since 
the disruption of mechanisms affected by these pathways 
may lead to pathogenic events (Mocellin, Valpione, Rossri, 
& Pooley, 2018; Nicolini, 2017.; Ziv et al., 2017). The de-
scription of these changes is very relevant from the point of 
view of genetic susceptibility.
Alternative splicing has been extensively linked to acti-
vation of many tumor processes, because RNA processing is 
vital for the production of variant proteins that are involved 
in steps such as angiogenesis, invasion, and antiapoptosis. 
These processes are also influenced not only by genetic but 
also environmental factors, for example, chemical and im-
mune responses, heat stress, and DNA damage (Anczuków & 
Krainer, 2016; Pai & Luca, 2018). Copy number alterations 
were described as having a particular association to alter-
native splicing, especially large ones, as seen in our study 
(Sebestyén et al., 2016; Singh & Eyras, 2017). Also, heredi-
tary breast cancer was reported as enriched for splicing mu-
tations, what often leads to loss of functions in cancer (Rhine 
et al., 2018).
Thus, in relation to clinical features, namely histologi-
cal type, ethnicity, disease stage, and familial history, there 
are particularities worth pointing out. As previously stated, 
CNVs in chromosomes 1, 8, 17, 19, and 21 explain around 
half of the alterations found in these samples when associ-
ated with one of these clinical characteristics. Alterations in 
chromosome 1 have been described in 50%–60% of breast 
tumors and are associated with disease initiation, presence 
of amplification sites, and a large number of copy number 
alterations, especially in the 1q arm, which harbor many 
oncogenes as MYCL1, JUN, NRAS, SHC1, and NCSTN, 
for example, all verified in samples from our current study 
(Goh et al., 2017; Orsetti et al., 2006; Silva et al., 2015). 
Chromosome 8p arm CNVs are widely linked to poor prog-
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recent studies showed that loss of multiple genes in this 
region may create greater genomic instability, leading to 
different effects from loss of a single gene (Cai et al., 2016; 
Lebok et al., 2015). These two chromosomes are mainly as-
sociated with differentiation of ductal and mucinous types, 
which explain why they were found linked to histological 
type alterations (Afghahi et al., 2015; Lacroix‐Triki et al., 
2010).
Ethnicity was found to be associated with CNVs on 
chromosomes 1 and 17. A recent study suggests that genes 
near BRCA1 in 17q are correlated with breast cancer in 
African Americans (Ochs‐Balcom et al., 2015). However, 
there is a lack of studies that confirm this association, 
although genes related to heredity could also contribute 
to this finding. Interestingly, familial history presence 
correlated mainly to CNVs in chromosome 21. The gene 
NRIP1 localized at 21q21 was described to be a suscepti-
bility locus (Ghoussaini et al., 2012) and this region was 
among our identified CNVs. Also, other chromosome 21 
regions were identified, containing genes as SAMSN1, as-
sociated with several cancer types such as multiple my-
eloma, lung cancer, glioblastoma, and RUNX1, implicated 
as an oncogene and tumor suppressor in breast cancer 
(Browne et al., 2015; Mercado‐Matos, Matthew‐Onabanjo, 
& Shaw, 2017; Noll et al., 2014; Yamada et al., 2008; Yan 
et al., 2013). Late disease stage was correlated to chromo-
some 19 copy number alterations. These regions have been 
described in association with high‐grade breast cancers 
for other studies (Yu, Kanaan, Bae, Baed, & Gabrielson, 
2009) and are characterized by aggressiveness and poor 
prognosis tumors.
Since this study focused on a Brazilian cohort, it is worth 
mentioning that the genetic composition of the Brazilian 
population is sharply mixed and is genomically underrepre-
sented in studies that consider variants and tumor markers 
(Popejoy & Fullerton, 2016). There might be considerable 
genetic differences underlying tumor biology in these cases, 
so it is critical to consider understudied populations to better 
understand breast cancer worldwide. Despite the restricted 
sample size, this is the first study to evaluate breast cancer 
CNVs in this specific population, associating them to tumor 
clinical features. CNV regions identified from these sam-
ples and their correlated genes could potentially be different 
from non‐Brazilian cohorts. In a previous study comparing 
Brazilian and TCGA (The Cancer Genome Atlas) data (data 
not shown), we found striking differences between these two 
cohorts, which were related to genes involved in different 
carcinogenic pathways, since pathways related to FGF and 
Feature Chr. Pathway/function Gene count % p‐value
Histological type 1 Alternative splicing 37 57.8 0.0017
Splice variant 29 45.3 0.0096
Cytoplasm 20 31.2 0.015
Mutagenesis site 11 17.2 0.041
8 Polymorphism 87 55.1 0.021
Alternative splicing 81 51.3 0.0056
Phosphoprotein 69 43.7 0.0014
Splice variant 67 42.4 0.0012
Cytoplasm 44 27.8 0.0047
Familial history 21 Alternative splicing 40 40.8 0.0043
Phosphoprotein 35 35.7 0.0014
Protein binding 32 32.7 0.038
Nucleus 28 28.6 0.0003
Cytosol 18 18.4 0.0055
Disease stage 19 Polymorphism 224 53.8 0.013
Nucleus 149 35.8 1E‐12
Transcription 118 28.4 4E‐28
Metal binding 117 28.1 6E‐13
DNA binding 106 25.5 1E‐26
Ethinicity 1 Alternative splicing 33 60.0 0.024
Splice variant 28 50.9 0.01
Ubl conjugation 10 18.2 0.016
17 Splice variant 12 54.5 0.0028
T A B L E  4  Functional annotation of 
genes and enriched pathways associated 
with CNVs described (DAVID 6.8 
Database)
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Wnt were most commonly affected in the Brazilian sam-
ples, whereas those associated with cholecystokinin receptor 
(CCKR) signaling and inflammation mediated by chemokine 
and cytokine signaling pathways were most commonly af-
fected in the TCGA samples.
We conclude that the copy number alterations described 
in this study provide an overview of the chromosomal regions 
affected by CNVs and their association with clinical and 
pathological features. New molecular targets can be inferred 
from this study and these CNV regions should be investigated 
in more detail, potentially driving more dedicated studies fo-
cusing on breast tumors from Brazilian cohorts.
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